Patients with Raynaud's phenomenon suffer from painful attacks triggered by stress or cold causing acute lowering of blood flow through the digits. In this trial the safety and efficacy as well as the effect of one dose of the sGC stimulator Riociguat on digital blood flow will be measured during a cold exposure test in patients suffering from Raynaud's phenomenon. Measurements of two periods will be compared: in one period the patient will be given active drug and in the other period a placebo.
- Patients suffering from Raynaud’s phenomenon diagnosed at least ≥1 year before beginning of the study of the following origin: -- idiopathic (primary) -- limited cutaneous Scleroderma associated -- diffuse cutaneous Scleroderma associated -- mixed connective tissue disease associated
- Patients taking medication interfering with the digital flow measurement such as calcium channel blockers (CCB), phosphodiesterase 5 (PDE5) inhibitors, endothelin receptor antagonists (ERA), Nitrates - Smokers - Systolic blood pressure (SBP) below 105mmHg at rest
Köln, Germany, 50937
E-mail: [email protected]
Phone: Not Available
Single dose, double-blind, placebo-controlled, single center, randomized cross-over study to investigate safety, tolerability, pharmacodynamics and pharmacokinetic properties of BAY63-2521 after oral dosing of a 2 mg IR tablet in 20 patients with Raynaud’s phenomenon (RP)